Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Combination of Insulin and UC-MSCs Secretome Therapy Demonstrates A Trend of Liver Injury Improvement in Diabetic Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) Rat Model

The Indonesian Biomedical Journal · Vol. 18 No. 4 (2026) · hlm. 332–343

DOI
10.18585/inabj.v18i4.4287
ISSN
2085-3297, 2355-9179
Terbit
2026-08-31
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) coexists with diabetes mellitus and presents a significant therapeutic challenge due to its complex metabolic and hepatic pathology. Insulin therapy remains the cornerstone for glycemic management, but its effects on hepatic steatosis is inconsistent. Complementary therapies are needed to address this limitation. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) secretome has emerged as therapeutic approach for metabolic disease due to its anti-inflammatory, immunomodulatory, and antioxidant properties. This study was conducted to evaluate whether adjunctive administration of UC-MSCs secretome could enhance therapeutic outcomes, particularly in alleviating hepatic steatosis in a diabetic MASLD rat model.METHODS: Male rats were grouped into normal and diabetic MASLD rat model, and treated with either growth medium, insulin, UC-MSCs secretome, or combination of insulin and UC-MSCs secretome for 4 weeks. Blood samples were collected and liver enzymatic and lipid profile were analyzed using chemistry analyzer. Liver tissue was also obtained for assessment of liver fibrosis using Hematoxylin-Eosin staining, interleukin (IL)-6 measurement using enzyme-linked immunosorbent assay (ELISA), and superoxide dismutase (SOD) activity measurement using colorimetry.RESULTS: Combined insulin and UC-MSCs secretome therapy showed a trend toward better blood glucose management and lipid parameters, although not statistically significant. Administration of insulin, secretome, and their combination was associated with higher hepatic SOD levels and lower IL-6 protein levels, although not statistically significant. Combined therapy also reduced hepatomegaly compared to untreated diabetic MASLD rat model, and improved hepatic steatosis while significantly alleviating fibrosis severity.CONCLUSION: Combination of insulin and UC-MSCs secretome therapy in diabetic MASLD was able to improve several parameters related to hepatic steatosis compared with the untreated diabetic MASLD rat model. These findings suggest that UC-MSCs secretome might serve as a potential adjunct to insulin therapy.KEYWORDS: metabolic dysfunction-associated steatotic liver disease, type 2 diabetes, cell free therapy, umbilical cord mesenchymal stem cells, secretome

Kata kunci

Jaringan kolaborasi para penulis

13 penulis · 31 tautan kepenulisan bersama · 4 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Tarumanagara University
  • Binus University
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Bryan Anna WijayaTarumanagara University2
Yohanes FirmansyahTarumanagara University2
Fiona Valencia SetiawanAfiliasi tidak diketahui1
Johan JohanBinus University1
Oentarini TjandraTarumanagara University1
Marcella Erwina RumawasTarumanagara University1
Fia Fia LieTarumanagara University1
Agus LimartaAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Combination of Insulin and UC-MSCs Secretome Therapy Demonstrates A Trend of Liver Injury Improvement in Diabetic Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) Rat Model</dc:title><dc:creator>Shirly Gunawan</dc:creator><dc:creator>Siufui Hendrawan</dc:creator><dc:creator>Olivia Marcelina</dc:creator><dc:creator>Jennifer Lheman</dc:creator><dc:creator>Hans Ulrich Baer</dc:creator><dc:subject>non-alcoholic fatty liver disease</dc:subject><dc:subject>type 2 diabetes</dc:subject><dc:subject>insulin therapy</dc:subject><dc:subject>human umbilical cord mesenchymal stem cells</dc:subject><dc:subject>secretome</dc:subject><dc:subject>cell-free therapy</dc:subject><dc:subject>hepatic steatosis</dc:subject><dc:subject>liver fibrosis</dc:subject><dc:subject>hepatomegaly</dc:subject><dc:subject>interleukin-6</dc:subject><dc:subject>superoxide dismutase</dc:subject><dc:subject>oxidative stress</dc:subject><dc:subject>combination therapy</dc:subject><dc:subject>rat model</dc:subject><dc:description xml:lang="en">BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) coexists with diabetes mellitus and presents a significant therapeutic challenge due to its complex metabolic and hepatic pathology. Insulin therapy remains the cornerstone for glycemic management, but its effects on hepatic steatosis is inconsistent. Complementary therapies are needed to address this limitation. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) secretome has emerged as therapeutic approach for metabolic disease due to its anti-inflammatory, immunomodulatory, and antioxidant properties. This study was conducted to evaluate whether adjunctive administration of UC-MSCs secretome could enhance therapeutic outcomes, particularly in alleviating hepatic steatosis in a diabetic MASLD rat model.METHODS: Male rats were grouped into normal and diabetic MASLD rat model, and treated with either growth medium, insulin, UC-MSCs secretome, or combination of insulin and UC-MSCs secretome for 4 weeks. Blood samples were collected and liver enzymatic and lipid profile were analyzed using chemistry analyzer. Liver tissue was also obtained for assessment of liver fibrosis using Hematoxylin-Eosin staining, interleukin (IL)-6 measurement using enzyme-linked immunosorbent assay (ELISA), and superoxide dismutase (SOD) activity measurement using colorimetry.RESULTS: Combined insulin and UC-MSCs secretome therapy showed a trend toward better blood glucose management and lipid parameters, although not statistically significant. Administration of insulin, secretome, and their combination was associated with higher hepatic SOD levels and lower IL-6 protein levels, although not statistically significant. Combined therapy also reduced hepatomegaly compared to untreated diabetic MASLD rat model, and improved hepatic steatosis while significantly alleviating fibrosis severity.CONCLUSION: Combination of insulin and UC-MSCs secretome therapy in diabetic MASLD was able to improve several parameters related to hepatic steatosis compared with the untreated diabetic MASLD rat model. These findings suggest that UC-MSCs secretome might serve as a potential adjunct to insulin therapy.KEYWORDS: metabolic dysfunction-associated steatotic liver disease, type 2 diabetes, cell free therapy, umbilical cord mesenchymal stem cells, secretome</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2026-08-31</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.18585/inabj.v18i4.4287</dc:identifier><dc:identifier>10.18585/inabj.v18i4.4287</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 18 No 4 (2026); 332-343</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/4287/859</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>